The FirstTake Podcast – KRAS, OX40, EQRx and ASCO in focus
FirstTake on Pharma - Pharma News and Analysis Podcast
English - June 03, 2021 22:00 - 28 minutes - 20.7 MB - ★★★★★ - 2 ratingsScience pharma pharmaceutical intelligence firstword firsttake cardiovascular dermatology diabetes immunology infectious diseases Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: The FirstTake Podcast – Will vaccine sales prime Pfizer for deal-making?
FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss FDA approval of the first KRAS inhibitor – Amgen’s Lumakras, the emergence of OX40 as an increasingly sought after target for investigational atopic dermatitis treatments, more clinical data to support EQRx’s price-disruptive push into oncology and look ahead to this weekend’s virtual ASCO meeting.